Acalabrutinib in mantle cell lymphoma
Mené sur 124 patients atteints d'un lymphome à cellules du manteau réfractaire ou récidivant (âge médian : 68 ans), cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse globale, et la toxicité de l'acalabrutinib, un inhibiteur de tyrosine kinase de Bruton (durée médiane de suivi : 13, 8 mois)
Mantle cell lymphoma is a rare, distinct subtype of non-Hodgkin lymphoma, with a disparate clinical course that varies from indolent at times to frequently aggressive. No standard of care exists; most patients relapse and ultimately die as a result of their disease. Notable strides in the past few years, however, have ushered an era of unprecedented progress, with swift approval of new therapies from a variety of drug classes. One such drug that has catapulted to prominence is ibrutinib, the first-in-class, irreversible inhibitor of Bruton tyrosine kinase (BTK), a crucial component of the B-cell-receptor signalling pathway that is implicated in the pathogenesis of mantle cell lymphoma.
The Lancet , commentaire, 2016